Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 13324: A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-Line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma.

99 years and younger
All genders
This is a phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab for the first-line (1L) treatment of recurrent or metastatic, programmed cell death protein ligand 1+ (PD-L1+) head and neck squamous cell carcinoma (HNSCC) in patients with combined positive score (CPS) …
Learn More

UPCC 29424 Safety and Efficacy of Dual Menin and FLT3 Inhibition in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia Containing a Concurrent MLL-Rearrangement or NPM1 Mutation: A Phase 1 (Ph1) Study of SNDX-5613 + Gilteritinib

99 years and younger
All genders
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2.1 (Primary Endpoints). Please refer to Protocol Section 2.2 (Secondary Endpoints)
Learn More

UPCC 41424 Preliminary Investigation of -Hydroxybutyrate Supplementation for Lymphoma Patients Receiving Anti-CD19 CAR T-Cells (BHB & CAR-T for Lymphomas)

99 years and younger
All genders
Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints).
Learn More

EA7222: A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

99 years and younger
All genders
The EA7222 study is a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced UPS and related poorly differentiated sarcomas that cannot be removed by surgery (unresectable). The studys primary objective is to assess whether the combination therapy will improve PFS for this …
Learn More

UPCC 01523: A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treat

99 years and younger
All genders
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic …
Learn More

UPCC 02424: A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non- Hodgkin Lymphoma

99 years and younger
All genders
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: can a safe dose of JNJ-90009530 be determined that is safe and well tolerated by patients. will JNJ-90009530 help patients achieve a response and …
Learn More

UPCC 14224: A Single-Arm, Multicenter Phase 2 Study of Neoadjuvant Pembrolizumab with Trastuzumab and Chemotherapy in Resectable HER2+ Esophagogastric Tumors

99 years and younger
All genders
Please refer to Protocol Section 2.0 (Objectives and Scientific Aims). Please refer to Protocol Section 14.0 (Biostatistics). Please refer to Protocol Section 14.0 (Biostatistics).
Learn More

UPCC MM1OA-EA02: A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

99 years and younger
All genders
To compare the achievement rate of MRDneg CR of either triplet regimen to azacitidine and venetoclax alone within 4 cycles of therapy.
Learn More

UPCC 43424: A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitini

99 years and younger
All genders
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.
Learn More

UPCC 26124 A Phase 2 Study of Alisertib in Combination with Endocrine Therapy in Patients with HR+, HER2-Negative Recurrent or Metastatic Breast Cancer

99 years and younger
All genders
This is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended …
Learn More
191 - 200 of 206